X

WM-Aktion Trotz Niederlage: Dein WM-Bonus steigt auf 75 €

Deutschland patzt, du punktest: Eröffne jetzt dein Depot bei unserem Broker finanzen.net ZERO und sichere dir 25 € WM-Startbonus auf dein Cash-Konto
+ 5 € WM-Torbonus für jeden deutschen Treffer* (aktuell + 50 €)
Starte jetzt beim Kostensieger der Stiftung Warentest (12/2025) – Promocode

WM-Aktion ansehen Direkt starten

* Beachte die Aktions- & Teilnahmebedingungen. Tore in der Verlängerung und im Elfmeterschießen zählen nicht.

Nicht mehr anzeigen

Alk-Abello A-S Bearer and-or registered B Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

33,40 EUR -0,64 EUR -1,88 %

17:16:16

STU

33,44 EUR -0,78 EUR -2,28 %

17:27:42

GVIE

Alk-Abello A-S Bearer and-or registered B jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Smartphone

Marktkap.7,59 Mrd. EUR

KGV42,31Div. Rendite0,70%

WKNA3DHX9

ISINDK0061802139

SymbolAKBLF

Alk-Abello A-S Bearer and-or registered B Aktien News

Sortieren:Datum Meistgelesen

04.06.25GlobeNewswireALK participates at Jefferies Global Healthcare Conference 2025 in New York

08.05.25GlobeNewswireITULATEK® approved for treatment of children and adolescents in Canada

06.05.25GlobeNewswireThree-month interim report (Q1) 2025 (unaudited)

WerbungAlk-Abello A-S Bearer and-or registered B-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

02.05.25GlobeNewswireALK enters into neffy® co-promotion agreement in the USA

29.04.25GlobeNewswireInvitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

23.04.25GlobeNewswireITULAZAX® tree pollen tablet approved for treatment of children in Europe

03.04.25GlobeNewswireGrant of share-based long-term incentive instruments to members of the Board of Management and key employees

13.03.25GlobeNewswireAnnual General Meeting in ALK-Abelló A/S held on 13 March 2025

07.03.25GlobeNewswireACARIZAX® approved in Canada for treatment of young children

04.03.25GlobeNewswireReport on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

28.02.25PR NewswireU.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy

27.02.25GlobeNewswireFDA approves ODACTRA® for the treatment of house dust mite allergy in young children

21.02.25GlobeNewswireReport on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

19.02.25GlobeNewswireAnnual General Meeting in ALK-Abelló A/S on 13 March 2025

19.02.25GlobeNewswireAnnual report 2024: ALK delivers 15% sales growth with profits up 65%

12.02.25GlobeNewswireInvitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

30.01.25GlobeNewswireALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

20.12.24GlobeNewswireALK – Financial calendar for the 2025 financial year

18.12.24GlobeNewswirePositive results advance peanut tablet to phase II development

12.12.24GlobeNewswireACARIZAX® approved in Europe for treatment of young children

27.11.24GlobeNewswireALK’s pivotal phase 3 trial in children published in reputable scientific journal

14.11.24GlobeNewswireNine-month interim report (Q3) 2024 (unaudited)

09.11.24GlobeNewswireALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

07.11.24GlobeNewswireInvitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

07.10.24PR NewswireALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis

27.08.24GlobeNewswireReport on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

22.08.24GlobeNewswireSix-month interim report (Q2) 2024

22.08.24GlobeNewswireALK upgrades its full-year revenue and earnings outlook

14.08.24GlobeNewswireInvitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024

21.06.24GlobeNewswireALK upgrades its full-year revenue and earnings outlook

21.06.24GlobeNewswireALK provides update on regulatory process for the house dust mite allergy tablet in China

03.06.24GlobeNewswireALK launches new growth strategy and 2028 financial ambitions

03.06.24GlobeNewswireALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies

30.05.24GlobeNewswireALK’s European registration application for ITULAZAX® for paediatric indication accepted for review

29.05.24GlobeNewswireListen in on ALK’s Capital Markets Day on 4 June 2024

02.05.24GlobeNewswireThree-month interim report (Q1) 2024 (unaudited)

02.05.24GlobeNewswireALK upgrades its full-year revenue outlook

24.04.24GlobeNewswireInvitation to the presentation of ALK’s first quarter results on Friday 3 May 2024

03.04.24GlobeNewswireGrant of share-based long-term incentive instruments to members of the Board of Management and key employees

26.03.24GlobeNewswireSave the date for ALK’s Capital Markets Day on 4 June 2024

Alk-Abello A-S Bearer and-or registered B News

Alk-Abello A-S Bearer and-or registered B News: auf dieser Seite finden Sie alle Alk-Abello A-S Bearer and-or registered B News und Nachrichten zur Alk-Abello A-S Bearer and-or registered B Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Alk-Abello A-S Bearer and-or registered B News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Alk-Abello A-S Bearer and-or registered B News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.